SPY330.71+4.05 1.24%
DIA267.11+1.63 0.61%
IXIC11,201.05+196.18 1.78%

Morgan Stanley Maintains Overweight on Genmab, Raises Price Target to $35

Morgan Stanley maintains Genmab (NASDAQ:GMAB) with a Overweight and raises the price target from $32 to $35.

· 10/13/2020 09:30
Morgan Stanley maintains Genmab (NASDAQ:GMAB) with a Overweight and raises the price target from $32 to $35.